Features of the dopaminergic neurotoxin MPTP.
Kopin
I J
IJ
National Institutes of Health, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland 20892.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000378:metabolism; D015655:1-Methyl-4-phenylpyridinium / Q000633:toxicity; D000818:Animals; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D002118:Calcium / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D005609:Free Radicals; D006801:Humans; D020267:MPTP Poisoning; D009474:Neurons / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D009498:Neurotoxins
D005609:Free Radicals; D009498:Neurotoxins; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015655:1-Methyl-4-phenylpyridinium; D002118:Calcium; D004298:Dopamine